1. Home
  2. INSM vs A Comparison

INSM vs A Comparison

Compare INSM & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$163.99

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Logo Agilent Technologies Inc.

A

Agilent Technologies Inc.

HOLD

Current Price

$136.01

Market Cap

39.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
INSM
A
Founded
1988
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
41.2B
39.8B
IPO Year
2000
1999

Fundamental Metrics

Financial Performance
Metric
INSM
A
Price
$163.99
$136.01
Analyst Decision
Strong Buy
Buy
Analyst Count
22
16
Target Price
$187.30
$165.13
AVG Volume (30 Days)
3.9M
2.0M
Earning Date
02-19-2026
02-25-2026
Dividend Yield
N/A
0.73%
EPS Growth
N/A
3.16
EPS
N/A
4.57
Revenue
$447,022,000.00
$6,948,000,000.00
Revenue This Year
$49.51
$8.02
Revenue Next Year
$134.47
$6.28
P/E Ratio
N/A
$30.56
Revenue Growth
30.34
6.73
52 Week Low
$60.40
$96.43
52 Week High
$212.75
$160.27

Technical Indicators

Market Signals
Indicator
INSM
A
Relative Strength Index (RSI) 37.15 36.25
Support Level $168.01 $143.14
Resistance Level $186.74 $150.10
Average True Range (ATR) 6.81 3.69
MACD -0.81 -0.37
Stochastic Oscillator 25.51 5.24

Price Performance

Historical Comparison
INSM
A

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About A Agilent Technologies Inc.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Share on Social Networks: